Valsartan
Mostrando 1-11 de 11 artigos, teses e dissertações.
-
1. Simultaneous Quantification of Amorphous and Crystalline Valsartan in Tablets Using Raman Spectroscopy and Chemometrics Tools
Valsartan is an antihypertensive active pharmaceutical ingredient (API), it is used in the amorphous state in the commercial products. As amorphous materials are metastable, amorphous valsartan can crystallize to valsartan E, promoting changes in the dissolution and bioavailability of the drug. Tablets containing metastable forms of APIs need special conditi
Journal of the Brazilian Chemical Society. Publicado em: 2022
-
2. Circulating microparticles and central blood pressure according to antihypertensive strategy
OBJECTIVES: This prospective, randomized, open-label study aimed to compare the effects of antihypertensive treatment based on amlodipine or hydrochlorothiazide on the circulating microparticles and central blood pressure values of hypertensive patients. METHODS: The effects of treatments on circulating microparticles were assessed during monotherapy and a
Clinics. Publicado em: 11/11/2019
-
3. The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
Arq. Bras. Cardiol.. Publicado em: 15/07/2019
-
4. YAP activation promotes the transdifferentiation of cardiac fibroblasts to myofibroblasts in matrix remodeling of dilated cardiomyopathy
Yes-associated protein (YAP) is an important regulator of cellular proliferation and transdifferentiation. However, little is known about the mechanisms underlying myofibroblast transdifferentiation in dilated cardiomyopathy (DCM). We investigated the role of YAP in the pathological process of cardiac matrix remodeling. A classic model of DCM was established
Braz J Med Biol Res. Publicado em: 23/11/2018
-
5. Continuous wavelet transform methods for the simultaneous determinations and dissolution profiles of valsartan and hydrochlorothiazide in tablets
ABSTRACT Continuous wavelet transform (CWT) was proposed for the simultaneous determination and dissolution profiles of valsartan (VAL) and hydrochlorothiazide (HCT) in tablets, without the use of a chemical separation procedure. The CWT approach was applied to the original UV spectra and their ratio spectra in the optimal wavelength ranges. After testing se
Braz. J. Pharm. Sci.. Publicado em: 20/04/2017
-
6. LC-MS characterization of valsartan degradation products and comparison with LC-PDA
resumo Valsartana (VAL) foi submetida à degradação forçada em meio ácido conforme procedimento descrito no ICH. Os produtos de degradação (PDs) foram monitorados ao longo do tempo de degradação pela técnica de Cromatografia Líquida (LC) utilizando uma coluna Hypersil ODS (C18) (250 x 4,6 mm d.i., 5 µm). A detecção foi feita com dois detectores:
Braz. J. Pharm. Sci.. Publicado em: 2015-12
-
7. Compatibility and stability of valsartan in a solid pharmaceutical formulation
Valsartana (VAL) é um bloqueador altamente seletivo do receptor da angiotensina II, que tem sido amplamente utilizado para o tratamento da hipertensão. Testes de compatibilidade com excipientes usualmente empregados em formulações sólidas são utilizados no desenvolvimento de formulações sólidas. Neste trabalho, realizaram-se testes utilizando mistur
Braz. J. Pharm. Sci.. Publicado em: 2013-12
-
8. HPLC method development for the simultaneous analysis of amlodipine and valsartan in combined dosage forms and in vitro dissolution studies
Desenvolveu-se método de HPLC rápido e reprodutível para a determinação simultânea de anlodipino e valsartana em suas formas de associação e para os estudos de dissolução dos fármacos. Utilizaram-se coluna C18 (ODS 2, 10 μm, 200 x 4,6 mm) e fase móvel tampão fosfato (pH 3,6, 0,01 mol L-1):acetonitrila: metanol para a separação e a quantifica�
Brazilian Journal of Pharmaceutical Sciences. Publicado em: 2010-12
-
9. Biodisponibilidade comparativa de duas formulações de losartan em voluntarios humanos sadios apos administração de dose unica / Comparative bioavailability of two losartan formulations in healthy human volunteers after a single dose administration
This dissertation focus in the evaluation of the bioavailability of two formulations of potassium losartan immediate release tablet 50mg (Losartan from Laboratórios Cristália Ltd., Brazil, as a test formulation and Cozaar® from Merck Sharp &Dohme Farmacêutica Ltd., Brazil as a reference formulation). The bioequivalence study was conducted using an open,
Publicado em: 2009
-
10. ELITE II and Val-HeFT are different trials: together what do they tell us?
The Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT) both evaluated the efficacy and tolerability of a selective angiotensin II receptor antagonist on morbidity and mortality in patients with symptomatic heart failure. The trials differed, however, in terms of their primary hypothesis, study design, and treatm
BioMed Central.
-
11. Human adipocytes secrete mineralocorticoid-releasing factors
Obesity has become an epidemic problem in western societies, contributing to metabolic diseases, hypertension, and cardiovascular disease. Overweight and obesity are frequently associated with increased plasma levels of aldosterone. Recent evidence suggests that human fat is a highly active endocrine tissue. Therefore, we tested the hypothesis that adipocyte
National Academy of Sciences.